OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

South Korea flag South Korea · Delayed Price · Currency is KRW
6,830.00
-10.00 (-0.15%)
At close: Dec 5, 2025
28.87%
Market Cap 120.53B
Revenue (ttm) 87.58B
Net Income (ttm) 11.18B
Shares Out 17.65M
EPS (ttm) 730.71
PE Ratio 9.35
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,343
Average Volume 61,843
Open 6,850.00
Previous Close 6,840.00
Day's Range 6,780.00 - 6,890.00
52-Week Range 4,855.00 - 8,960.00
Beta 0.40
RSI 47.00
Earnings Date Jan 23, 2026

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 2002
Employees 159
Stock Exchange KOSDAQ
Ticker Symbol 131030
Full Company Profile

Financial Performance

In 2024, OPTUS Pharmaceutical's revenue was 81.90 billion, an increase of 13.09% compared to the previous year's 72.43 billion. Earnings were 10.31 billion, a decrease of -4.20%.

Financial Statements

News

There is no news available yet.